EC approves Sarclisa in combination with VRd for transplant-eligible newly diagnosed MM

FDA grants accelerated approval to iberdomide combination for MM

FDA granted accelerated approval to iberdomide (Zenbexus) in combination with daratumumab and hyaluronidase-fihj and dexamethasone for adults with multiple myeloma who have received at least one prior line of therapy including a proteasome inhibitor and an immunomodulatory agent.

September 11, 2026

Vol.52 No.33

Drugs & Targets

EC approves Trodelvy + Keytruda for PD-L1 positive first-line metastatic TNBC

The European Commission has granted marketing authorization for Trodelvy (sacituzumab govitecan-hziy) in combination with Keytruda (pembrolizumab) for the treatment of adult patients with unresectable, locally advanced or metastatic triple-negative breast cancer who have not received prior systemic therapy for metastatic disease and whose tumors express PD-L1 with a combined positive score. Trodelvy plus Keytruda is...

September 11, 2026

Vol.52 No.33

Drugs & Targets

FDA grants accelerated approval to iberdomide with daratumumab and hyaluronidase-fihj and dexamethasone for multiple myeloma

August 14, 2026

Vol.52 No.32

Clinical Roundup

Lenalidomide maintenance may end after two years for patients with MM, phase III trial finds

For patients with newly diagnosed multiple myeloma not undergoing an autologous stem cell transplant, indefinite lenalidomide maintenance has long been standard of care, despite limited evidence to guide the optimal duration of treatment.

July 17, 2026

Vol.52 No.28

Drugs & Targets

FDA approves Sarclisa Escena for subcutaneous injection for multiple indications in MM

FDA approved Sarclisa Escena (isatuximab-irfc) for subcutaneous injection for multiple myeloma indications.

July 17, 2026

Vol.52 No.28

Clinical Roundup

First patient enrolls in MMRF’s Horizon Two clinical trial for newly diagnosed multiple myeloma treatment

The Multiple Myeloma Research Foundation announced that the first patient has been enrolled in the groundbreaking Horizon Two clinical trial that aims to identify the best treatments and treatment combinations for patients with high-risk, newly diagnosed multiple myeloma.

July 02, 2026

Vol.52 No.26

EC approves Sarclisa in combination with VRd for transplant-eligible newly diagnosed MM

YOU MAY BE INTERESTED IN

FDA grants accelerated approval to iberdomide combination for MM

EC approves Trodelvy + Keytruda for PD-L1 positive first-line metastatic TNBC

FDA grants accelerated approval to iberdomide with daratumumab and hyaluronidase-fihj and dexamethasone for multiple myeloma

Lenalidomide maintenance may end after two years for patients with MM, phase III trial finds

FDA approves Sarclisa Escena for subcutaneous injection for multiple indications in MM

First patient enrolls in MMRF’s Horizon Two clinical trial for newly diagnosed multiple myeloma treatment

Renew today!

Subscriber content

Never miss an issue!

Login